Search results
Novartis raises guidance after beating Q1 expectations By Reuters
Investing.com· 6 hours agoFRANKFURT (Reuters) -Swiss drugmaker Novartis (LON:0QLR) raised its full-year guidance on wider use...
Are your prescription drugs affordable? Colorado board wants feedback on these 2
KDVR Denver via Yahoo News· 5 days agoCosentyx, which treats psoriasis, and Stelara, for Crohn’s disease, are now under the microscope of...
Novartis shares jump as drugmaker boosts outlook
Market Watch· 4 hours agoNovartis shares rallied on Tuesday as the Swiss drugmaker raised its outlook for the year after seeing strong demand for heart and psoriasis drugs.
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Zacks via Yahoo Finance· 4 days agoSales of Cosentyx, too, have likely increased in the first quarter. In October 2023, the FDA...